ONCSQ (OncoSec Medical) Total Liabilities: $14.36 Mil (As of Jan. 2023)


What is OncoSec Medical Total Liabilities?

OncoSec Medical ONCSQ -99.00% Total Liabilities is $14.36 Mil as of Jan. 2023.

OncoSec Medical's Total Liabilities for the quarter that ended in Jan. 2023 was $14.36 Mil.

OncoSec Medical's quarterly Total Liabilities declined from Jul. 2022 ($15.76 Mil) to Oct. 2022 ($15.42 Mil) and declined from Oct. 2022 ($15.42 Mil) to Jan. 2023 ($14.36 Mil).

OncoSec Medical's annual Total Liabilities increased from Jul. 2020 ($16.03 Mil) to Jul. 2021 ($18.20 Mil) but then declined from Jul. 2021 ($18.20 Mil) to Jul. 2022 ($15.76 Mil).

OncoSec Medical Total Liabilities Historical Data

* Premium members only.

The historical data trend for OncoSec Medical's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OncoSec Medical Total Liabilities Chart

OncoSec Medical Annual Data
Trend Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.32 5.61 16.03 18.20 15.76

OncoSec Medical Quarterly Data
Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.27 14.11 15.76 15.42 14.36

OncoSec Medical Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

OncoSec Medical's Total Liabilities for the fiscal year that ended in Jul. 2022 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=6.633+(4.127+5
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=15.76

Total Liabilities=Total Assets (A: Jul. 2022 )-Total Equity (A: Jul. 2022 )
=21.878-6.118
=15.76

OncoSec Medical's Total Liabilities for the quarter that ended in Jan. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=7.231+(2.127+5
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=14.36

Total Liabilities=Total Assets (Q: Jan. 2023 )-Total Equity (Q: Jan. 2023 )
=8.871--5.486
=14.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $14.36 Mil mean?
OncoSec Medical (ONCSQ) has a Total Liabilities of $14.36 Mil as of Jan. 2023. The total amount of liabilities as recorded on a company's balance sheet. View historical data for OncoSec Medical and its competitors.
Is OncoSec Medical's Total Liabilities too high?
OncoSec Medical's current Total Liabilities is $14.36 Mil.
How does OncoSec Medical's Total Liabilities compare to NOVNQ and USRM?
OncoSec Medical's Total Liabilities of $14.36 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for OncoSec Medical and its competitors. OncoSec Medical's current Total Liabilities is $14.36 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoSec Medical stock overvalued right now?
OncoSec Medical (ONCSQ) has a current Total Liabilities of $14.36 Mil. The current Total Liabilities is $14.36 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For OncoSec Medical (ONCSQ), the current Total Liabilities is $14.36 Mil as of Jan. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

OncoSec Medical Business Description

Address 820 Bear Tavern Road, Ewing, NJ, USA, 08628-1021
OncoSec Medical Inc is a healthcare sector company. It is focused on designing, developing and commercializing gene therapies, therapeutics, and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple-negative breast cancer.